


Synthetic Biology of Natural Products

New Tools for Unlocking Nature's Medicine Cabinet



David Mead PhD

CEO & Cofounder

dmead@terrabioforge.com



Pharma Biotech

“Why is NP production so expensive?”




Agriculture


“Why does commercialization take so long?”




Animal Health



Low
Yields



Low
Margins



Long
Timelines



Consumer

Advantages of Engineered Natural Products




More affordable supply \$\$\$\$



Faster commercialization







Superior purity and quality



Potential for modification exploiting NP diversity

Biosynthetic Gene Clusters are:

- **Large** – up to 400,000 base pairs
- **Complicated** – dozens of genes
- **Difficult to discover** – genotype versus phenotype
- **Difficult to express** – many pathways are cryptic
- **Variable culture** – native host may not always be useful





Cloned and expressed by Terra Bioforge

DNAtrap™

Microbial BGC Cloning

PIONEERED “BIG DNA” TOOLS CAPTURING \$B NP PATHWAYS





- >150 BGCs cloned from >100 strains
- ~70% from Actinomycetota (high GC)
- ~10% from Bacillota
- Clusters from filamentous fungi (30-40 Mb genomes)
- Cluster sizes range from ~10–130 kb
- Refactoring BGCs
 - subcloning
 - insertions/deletions
 - promoter swaps

pDualP





Bacterial BGC Activation

How to cite: *Angew. Chem. Int. Ed.* **2023**, 62, e202304646
doi.org/10.1002/anie.202304646

Biosynthesis


Discovery of the Azaserine Biosynthetic Pathway Uncovers a Biological Route for α -Diazoester Production

Devon Van Cura, Tai L. Ng, Jing Huang, Harry Hager, John F. Hartwig, Jay D. Keasling, and Emily P. Balskus*




Harvard University
Devon Van Cura
Emily Balskus

Discovery of unreported β -amino acid macrotermycin derivatives




<https://www.nature.com/articles/s42004-023-01034-w>

Chalkophomycin BGC Expression Identified New N-nitrosating Enzymes




<https://www.biorxiv.org/content/10.1101/2024.01.24.577118v1.abstract>

Heterologous expression of seongomycin allowed assessment of its antibacterial, antiproliferative, and antiviral activities and revision of its structure



<https://pubs.rsc.org/en/content/articlehtml/2023/ra/d3ra05931f>

Structure of a lasso peptide bound ETB receptor provides insights into the mechanism of GPCR inverse agonism






<https://www.biorxiv.org/content/10.1101/2023.12.30.573741v1.abstract>


BGC manipulations using AMA1

Native imizoquin (*imq*) cluster fails to heterologously express in *A. nidulans*

Promoter replacement (*OE*) activates a silent BGC for heterologous imizoquin production




Targeted Cloning and Metabologenomics Demystifies Pestalamide Biosynthesis



nature chemical biology

**Correlative metabologenomics of 110 fungi
reveals metabolite–gene cluster pairs**



Pestalamide B

Validated Metabologenomics Platform

Resolved correct biosynthetic pathway for pestalamide


<https://www.nature.com/articles/s41589-023-01276-8>

MycoDrive Technology

Fastest Synbio Tool for Increasing Fungal NP Titters

MycoDrive™ TECHNOLOGY

The fastest synthetic biology tool for increasing fungal natural product titer.



Applications & Benefits Include:

- Higher titer screening of biosynthetic pathways
- Flexible engineering in native or heterologous hosts
- COGS savings on existing products
- Faster prototyping and scaleup


MycoDrive Consistently Generates Multiple Genome Copies

Payloads		Payload Copy Number			Heterologous Production?
		Lowest	Average	Highest	
BGC	BIK (18.6 kbp)	5.4	18.7	48.2	Yes
	PST (37.9 kbp)	1.4	6.3	24.8	Yes
	ENF (42.3 kbp)	1.4	7.8	28.9	No
	CsA <i>simA</i> (45.8 kbp)	2.2	12.8	27.7	Yes
	CsA 2nd 1/2 (47.9 kbp)	7.4	15.2	30.9	
Enzyme	XynA (2 kbp)	1.0	4.3	31.6	Yes

MycoDrive Case Study

Heterologous Production of Bikaverin

**Captured intact
Bikaverin BGC from
F. oxysporum gDNA**




Cloned 3 Ways

Targeted Integration

Episomal (Plasmid)


MycoDrive™



MycoDrive™ quickly attains highest titer

- No BGC refactoring – this example
- Straightforward cloning – no HOM arms or dealing with AMA1 repeats
- More high-producing clones per transformation – less time screening

PIONEERED “BIG DNA” TOOLS FOR PRODUCING \$B DRUGS




MycoDrive™ Technology

**35X MORE PRODUCT
Higher profits**



**10-20X FASTER
Months NOT Years**

BGC Copy Number Positively Correlates with NP Production Levels

BGC Copy Number Vs Bikaverin Concentration




MycoDrive Recombinant Cyclosporine Accelerates Drug Production



Strain 10.4 was wild type and barely made CsA


Strain 10.4.1 and .2 was a constitutive promoter swap in regulatory gene That improved yield 84X, same as native strain!



3d = Terra Bioforge
14d = Industry Std
10X Yield = Next Gen



Recombinant Cyclosporine!

Cyclosporine Standard



Tolypocladium producer strain

Recombinant Cyclosporine




MycoDrive™ Fungal Engineering

A New SynBio Tool for High Product Titters

Incumbent Technologies

	Integration Mechanism	Overexpression Strategy	Genetic Stability	Titer Potential	Scalability/ Throughput	Technical Complexity	Cost/ Burden
MycoDrive	Proprietary	Multiple Copies	High	High	High	Low	Low
Targeted Integration	DNA Repair	Strong/Inducible Promoters	High	Low	Low	High	High
Random Integration	DNA Repair	Copy Number	Medium	High	Medium	Low	Medium
Ama1	n/a	Strong/Inducible Promoters	Low	Medium	High	Medium	Medium

Conventional 6-APA Production from Pen G



6-APA (6-aminopenicillanic acid) is made by enzymatic removal of the side chain from penicillin G using penicillin G acylase, followed by purification steps to isolate the product for use in antibiotic synthesis.

- Fermentation to produce penicillin G which is recovered, purified, and crystallized.
- Enzymatic hydrolysis of penicillin G using *penicillin G acylase*, yielding 6-APA and phenylacetic acid as products.
- Separation of 6-APA from enzyme and byproducts which is crystallized.

Penicillium rubens Strain Engineering to Make 6-APA and/or Amoxicillin and Ampicillin Directly

P. rubens is the "ancestral" penicillium strain and an ideal host for adding the right balance of pathways to achieve new capabilities:

- Fermentation to produce 6-APA directly.
- or-
- Fermentation to produce Amoxicillin or Ampicillin directly.

Benefits of Terra Bioforge Fungal Genome Engineering

Streamlined strain engineering

- BIGDNA™ capabilities are ideal inputs for size-agnostic payload integrations
- Proven pSMART BAC vectors are now updated for higher heterologous titer
- Bypasses limitations of traditional multicopy and single copy integration methods generating high-value production strains faster than ever before

Highest capacity for transcriptional overexpression

- Guided integration into active chromatin
- Select for a range of integrations for fine-tuned performance
- Can easily clone new promoters in front of key BGC components (i.e., TFs, core enzyme, precursor bottleneck, etc...) for additional layers of control

High, stable production titers

- Stable maintenance of heterologous cargo independent of selection
- Identify titer improvements and commercial viability early in the R&D process
- Alleviating existing limitations of attaining high, stable transcription accelerates downstream bottleneck identification and abrogation